BofA analyst Joanna Gajuk lowered the firm’s price target on Select Medical (SEM) to $18 from $22 and keeps a Buy rating on the shares. The firm lowered its price target citing a lower multiple given the continued pressures in the Critical Illness Recovery Hospitals, but believes that Inpatient Rehab Facility strength provides offsets while final Medicare regulation points to the pressure lessening starting in Q4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- Select Medical Updates Bylaws for Proxy Compliance
- Select Medical price target lowered to $14 from $15 at UBS
- Select Medical: Buy Rating Affirmed on Strong Financial Performance and Growth Prospects
- Select Medical Reports Strong Q2 2025 Earnings
- Select Medical’s Earnings Call: Growth Amid Challenges